ProCE Banner Activity

Rationale for NTRK Testing in Patients With Cancer

Podcast Episodes
In this podcast episode, join George D. Demetri, MD, and Alexander Drilon, MD, to learn why, when, and how to test for NTRK fusions in patients with diverse solid tumors.

Released: October 08, 2021

Expiration: October 07, 2022

Share

Faculty

George D. Demetri

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander E. Drilon

Alexander E. Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received funds for research support and consulting fees from Bayer, Ignyta, Loxo, and Roche, and serves as a member of the board of directors for Blueprint Medicines.

Alexander E. Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consulting fees from 14ner/Elevation Oncology, AbbVie, ArcherDX, AstraZeneca, AXIS, BeiGene, BergenBio, Blueprint Medicines, EMD Serono, Exelixis, Helsinn, Hengrui, Ignyta/Genentech/Roche, Liberum, Loxo/Bayer/Lilly, Melendi, Merus, Monopteros, MORE Health, Novartis, Nuvalent, Pfizer, Remedica, Repare RX, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; funds for research support from Exelixis, Foundation Medicine GlaxoSmithKline, Pfizer, PharmaMar, Taiho, and Teva; and other financial support or material from Boehringer Ingelheim, Merck, Merus, and Puma.